Skip to main content

Articles

Page 1 of 27

  1. Individuals with Down syndrome (DS) are increasingly eligible for clinical trial intervention, particularly for the treatment or prevention of Alzheimer disease (AD). Yet, little is known about research attitu...

    Authors: Ira T. Lott, Katharine A. Kirby, Eric Doran and Joshua D. Grill
    Citation: Alzheimer's Research & Therapy 2022 14:176
  2. Visinin-like protein 1 (VILIP-1) belongs to the group of emerging biomarkers with the potential to support the early diagnosis of Alzheimer’s disease (AD). However, studies investigating the differential diagn...

    Authors: Steffen Halbgebauer, Petra Steinacker, Daniel Riedel, Patrick Oeckl, Sarah Anderl-Straub, Jolina Lombardi, Christine A. F. von Arnim, Magdalena Nagl, Armin Giese, Albert C. Ludolph and Markus Otto
    Citation: Alzheimer's Research & Therapy 2022 14:175
  3. Robust and accessible biomarkers that can capture the heterogeneity of Alzheimer’s disease and its diverse pathological processes are urgently needed. Here, we undertook an investigation of Alzheimer’s disease...

    Authors: Eric B. Dammer, Lingyan Ping, Duc M. Duong, Erica S. Modeste, Nicholas T. Seyfried, James J. Lah, Allan I. Levey and Erik C. B. Johnson
    Citation: Alzheimer's Research & Therapy 2022 14:174
  4. The enrollment into clinical trials of persons at risk for autosomal dominant Alzheimer’s disease (ADAD) in whom the onset of disease can be accurately predicted facilitates the interpretation of outcomes (e.g...

    Authors: Angélica Zuno-Reyes, Esmeralda Matute, Karin Ernstrom, Mellissa Withers, Yaneth Rodriguez-Agudelo, Rema Raman and John M. Ringman
    Citation: Alzheimer's Research & Therapy 2022 14:173
  5. The recent promise of disease-modifying therapies for Alzheimer’s disease (AD) has reinforced the need for accurate biomarkers for early disease detection, diagnosis and treatment monitoring. Advances in the d...

    Authors: Edward N. Wilson, Christina B. Young, Javier Ramos Benitez, Michelle S. Swarovski, Igor Feinstein, Manu Vandijck, Yann Le Guen, Nandita M. Kasireddy, Marian Shahid, Nicole K. Corso, Qian Wang, Gabriel Kennedy, Alexandra N. Trelle, Betty Lind, Divya Channappa, Malia Belnap…
    Citation: Alzheimer's Research & Therapy 2022 14:172
  6. The effectiveness, safety, and cost-effectiveness of the use of Souvenaid for Alzheimer’s disease (AD) have been previously evidenced. To complete the economic analysis, there is a need to assess whether socie...

    Authors: Javier Mar, Oliver Ibarrondo, Igor Larrañaga, Lorea Mar-Barrutia and Myriam Soto-Gordoa
    Citation: Alzheimer's Research & Therapy 2022 14:171
  7. Early diagnosis of mild cognitive impairment (MCI) is essential for timely treatment planning. With recent advances in the wearable technology, interest has increasingly shifted toward computer-aided self-diag...

    Authors: Kyeonggu Lee, Kang-Min Choi, Seonghun Park, Seung-Hwan Lee and Chang-Hwan Im
    Citation: Alzheimer's Research & Therapy 2022 14:170
  8. Drug repositioning and repurposing has proved useful in identifying new treatments for many diseases, which can then rapidly be brought into clinical practice. Currently, there are few effective pharmacologica...

    Authors: John T. O’Brien, Leonidas Chouliaras, Janet Sultana, John-Paul Taylor and Clive Ballard
    Citation: Alzheimer's Research & Therapy 2022 14:169
  9. Telomere length (TL) is associated with biological aging, consequently influencing the risk of age-related diseases such as Alzheimer’s disease (AD). We aimed to evaluate the potential causal role of TL in AD ...

    Authors: Blanca Rodríguez-Fernández, Natalia Vilor-Tejedor, Eider M. Arenaza-Urquijo, Gonzalo Sánchez-Benavides, Marc Suárez-Calvet, Grégory Operto, Carolina Minguillón, Karine Fauria, Gwendlyn Kollmorgen, Ivonne Suridjan, Manuel Castro de Moura, David Piñeyro, Manel Esteller, Kaj Blennow, Henrik Zetterberg, Immaculata De Vivo…
    Citation: Alzheimer's Research & Therapy 2022 14:167
  10. Tau-PET is a prognostic marker for cognitive decline in Alzheimer’s disease, and the heterogeneity of tau-PET patterns matches cognitive symptom heterogeneity. Thus, tau-PET may allow precision-medicine predic...

    Authors: Davina Biel, Ying Luan, Matthias Brendel, Paul Hager, Anna Dewenter, Alexis Moscoso, Diana Otero Svaldi, Ixavier A. Higgins, Michael Pontecorvo, Sebastian Römer, Anna Steward, Anna Rubinski, Lukai Zheng, Michael Schöll, Sergey Shcherbinin, Michael Ewers…
    Citation: Alzheimer's Research & Therapy 2022 14:166
  11. Blood adiponectin and leptin are adipokines that emerged as potential biomarkers for predicting Alzheimer’s disease (AD) owing to their strong connection with obesity. Although obesity affects the relation bet...

    Authors: Keun You Kim, Junghee Ha, Minae Kim, So Yeon Cho, Hyunjeong Kim and Eosu Kim
    Citation: Alzheimer's Research & Therapy 2022 14:165
  12. Delaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics.

    Authors: José Viña, Joaquín Escudero, Miquel Baquero, Mónica Cebrián, Juan Antonio Carbonell-Asíns, José Enrique Muñoz, Encarnación Satorres, Juan Carlos Meléndez, José Ferrer-Rebolleda, Mª del Puig Cózar-Santiago, Jose Manuel Santabárbara-Gómez, Mariona Jové, Reinald Pamplona, Francisco José Tarazona-Santabalbina and Consuelo Borrás
    Citation: Alzheimer's Research & Therapy 2022 14:164
  13. Obstructive sleep apnoea (OSA) is the most frequent form of sleep-disordered breathing in patients with Alzheimer’s disease (AD). Available evidence demonstrates that both conditions are independently associat...

    Authors: Farida Dakterzada, Iván D. Benítez, Adriano Targa, Anna Carnes, Montse Pujol, Mariona Jové, Olga Mínguez, Rafi Vaca, Manuel Sánchez-de-la-Torre, Ferran Barbé, Reinald Pamplona and Gerard Piñol-Ripoll
    Citation: Alzheimer's Research & Therapy 2022 14:163
  14. Subjective cognitive decline (SCD) is a target for Alzheimer’s disease prediction. Plasma amyloid-beta oligomer (AβO), the pathogenic form of Aβ in blood, has recently been proposed as a novel blood-based biom...

    Authors: Keun You Kim, Jaesub Park, Yong Hyu Jeong, Hyun Jeong Kim, Eun Lee, Jin Young Park, Eosu Kim and Woo Jung Kim
    Citation: Alzheimer's Research & Therapy 2022 14:162
  15. The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients.

    Authors: Matthew Paul Lennol, Irene Sánchez-Domínguez, Inmaculada Cuchillo-Ibañez, Elena Camporesi, Gunnar Brinkmalm, Daniel Alcolea, Juan Fortea, Alberto Lleó, Guadalupe Soria, Fernando Aguado, Henrik Zetterberg, Kaj Blennow and Javier Sáez-Valero
    Citation: Alzheimer's Research & Therapy 2022 14:161
  16. Studies have reported higher plasma matrix metalloproteinase-9 (MMP-9) levels in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Despite evidence that MMP-9 activity and its influence on AD patho...

    Authors: Amaryllis A. Tsiknia, Erin E. Sundermann, Emilie T. Reas, Steven D. Edland, James B. Brewer, Douglas Galasko and Sarah J. Banks
    Citation: Alzheimer's Research & Therapy 2022 14:160
  17. Carefully conducted systematic reviews (SRs) can provide reliable evidence on the effectiveness of treatment strategies for Alzheimer’s disease (AD). Nevertheless, the reliability of SR results can be limited ...

    Authors: Claire C. W. Zhong, Jinglun Zhao, Charlene H. L. Wong, Irene X. Y. Wu, Chen Mao, Jerry W. F. Yeung and Vincent C. H. Chung
    Citation: Alzheimer's Research & Therapy 2022 14:159
  18. Microglia are the resident immune cells found in our brain. They have a critical role in brain maintenance. Microglia constantly scavenge various waste materials in the brain including damaged or apoptotic neu...

    Authors: Kyung Won Jo, Dohyun Lee, Dong Gon Cha, Eunji Oh, Yoon Ha Choi, Somi Kim, Eun Seo Park, Jong Kyoung Kim and Kyong-Tai Kim
    Citation: Alzheimer's Research & Therapy 2022 14:158
  19. The standard Centiloid (CL) method was proposed to harmonize and quantify global 18F-labeled amyloid beta (Aβ) PET ligands using MRI as an anatomical reference. However, there is need for harmonizing and quantify...

    Authors: Soo-Jong Kim, Hongki Ham, Yu Hyun Park, Yeong Sim Choe, Young Ju Kim, Hyemin Jang, Duk L. Na, Hee Jin Kim, Seung Hwan Moon and Sang Won Seo
    Citation: Alzheimer's Research & Therapy 2022 14:157
  20. The incidence of cognitive impairment is increasing with an aging population. Developing effective strategies is essential to prevent dementia. Higher education level is associated with better baseline cogniti...

    Authors: Yue Wang, Shinan Wang, Wanlin Zhu, Na Liang, Chen Zhang, Yuankun Pei, Qing Wang, Shiping Li and Jiong Shi
    Citation: Alzheimer's Research & Therapy 2022 14:156
  21. In the last decade, non-invasive blood-based and neurophysiological biomarkers have shown great potential for the discrimination of several neurodegenerative disorders. However, in the clinical workup of patie...

    Authors: Alberto Benussi, Valentina Cantoni, Jasmine Rivolta, Silvana Archetti, Anna Micheli, Nicholas Ashton, Henrik Zetterberg, Kaj Blennow and Barbara Borroni
    Citation: Alzheimer's Research & Therapy 2022 14:155
  22. Considerable overlap exists between the risk factors of dementia and cerebral small vessel disease (SVD). However, studies remain limited to older cohorts wherein pathologies of both dementia (e.g. amyloid) an...

    Authors: Audrey Low, Maria A. Prats-Sedano, Elizabeth McKiernan, Stephen F. Carter, James D. Stefaniak, Stefania Nannoni, Li Su, Maria-Eleni Dounavi, Graciela Muniz-Terrera, Karen Ritchie, Brian Lawlor, Lorina Naci, Paresh Malhotra, Clare Mackay, Ivan Koychev, Craig W. Ritchie…
    Citation: Alzheimer's Research & Therapy 2022 14:154
  23. Increasing evidence supports the use of plasma biomarkers of neurodegeneration and neuroinflammation to screen and diagnose patients with dementia. However, confirmatory studies are required to demonstrate the...

    Authors: Simone Baiardi, Corinne Quadalti, Angela Mammana, Sofia Dellavalle, Corrado Zenesini, Luisa Sambati, Roberta Pantieri, Barbara Polischi, Luciano Romano, Matteo Suffritti, Giuseppe Mario Bentivenga, Vanda Randi, Michelangelo Stanzani-Maserati, Sabina Capellari and Piero Parchi
    Citation: Alzheimer's Research & Therapy 2022 14:153
  24. Chronic neuroinflammation is one of the hallmarks of late-onset Alzheimer’s disease (AD) dementia pathogenesis. Carrying the apolipoprotein ε4 (APOE4) allele has been associated with an accentuated response to br...

    Authors: Brandon Ebright, Isaac Assante, Roy A. Poblete, Shaowei Wang, Marlon V. Duro, David A. Bennett, Zoe Arvanitakis, Stan G. Louie and Hussein N. Yassine
    Citation: Alzheimer's Research & Therapy 2022 14:152
  25. Frontotemporal dementia (FTD) covers a spectrum of neurodegenerative disorders with various clinical and neuropathological subtypes. The two major pathological proteins accumulating in the brains of FTD patien...

    Authors: Kasper Katisko, Nadine Huber, Tarja Kokkola, Päivi Hartikainen, Johanna Krüger, Anna-Leena Heikkinen, Veera Paananen, Ville Leinonen, Ville E. Korhonen, Seppo Helisalmi, Sanna-Kaisa Herukka, Valentina Cantoni, Yasmine Gadola, Silvana Archetti, Anne M. Remes, Annakaisa Haapasalo…
    Citation: Alzheimer's Research & Therapy 2022 14:151
  26. PPARγ agonists have been proven to be neuroprotective in vitro and in vivo models of Alzheimer’s disease (AD). In the present study, we identified ligustrazine piperazine derivative (LPD) as a novel PPARγ agon...

    Authors: Zongyang Li, Xiangbao Meng, Guoxu Ma, Wenlan Liu, Weiping Li, Qian Cai, Sicen Wang, Guodong Huang and Yuan Zhang
    Citation: Alzheimer's Research & Therapy 2022 14:150
  27. Chronic heart failure (HF) is known to increase the risk of developing Alzheimer’s dementia significantly. Thus, detecting and preventing mild cognitive impairment, which is common in patients with HF, is of g...

    Authors: Jan Traub, Markus Otto, Roxane Sell, Dennis Göpfert, György Homola, Petra Steinacker, Patrick Oeckl, Caroline Morbach, Stefan Frantz, Mirko Pham, Stefan Störk, Guido Stoll and Anna Frey
    Citation: Alzheimer's Research & Therapy 2022 14:149
  28. Imbalanced synaptic transmission appears to be an early driver in Alzheimer’s disease (AD) leading to brain network alterations. Early detection of altered synaptic transmission and insight into mechanisms cau...

    Authors: Monica van den Berg, Mohit H. Adhikari, Marlies Verschuuren, Isabel Pintelon, Tamara Vasilkovska, Johan Van Audekerke, Stephan Missault, Loran Heymans, Peter Ponsaerts, Winnok H. De Vos, Annemie Van der Linden, Georgios A. Keliris and Marleen Verhoye
    Citation: Alzheimer's Research & Therapy 2022 14:148
  29. Resting heart rate (RHR) has been linked with an increased risk of dementia. However, evidence characterizing the associations of RHR with different dementia subtypes and their underlying mechanisms remains sc...

    Authors: Yue-Ting Deng, Kevin Kuo, Bang-Sheng Wu, Ya-Nan Ou, Liu Yang, Ya-Ru Zhang, Shu-Yi Huang, Shi-Dong Chen, Yu Guo, Rui-Qi Zhang, Lan Tan, Qiang Dong, Jian-Feng Feng, Wei Cheng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2022 14:147
  30. Previous studies found that cancer survivors had a reduced risk of dementia compared with the general population. However, these findings were uncertain because of survivor bias and a lack of stratification by...

    Authors: Dan-Dan Zhang, Ya-Nan Ou, Liu Yang, Ya-Hui Ma, Lan Tan, Jian-Feng Feng, Wei Cheng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2022 14:146
  31. The relationship of specific body composition in the thighs and brain amyloid-beta (Aβ) deposition remained unclear, although there were growing evidence that higher muscle and fat mass in thighs had a protect...

    Authors: Sung Hoon Kang, Kyung Hyun Lee, Yoosoo Chang, Yeong Sim Choe, Jun Pyo Kim, Hyemin Jang, Hee Young Shin, Hee Jin Kim, Seong-Beom Koh, Duk L. Na, Sang Won Seo and Mira Kang
    Citation: Alzheimer's Research & Therapy 2022 14:145
  32. Cortical atrophy is associated with cognitive decline, but the association is not perfect. We aimed to identify factors explaining the discrepancy between the degree of cortical atrophy and cognitive decline i...

    Authors: Anna Linnéa Svenningsson, Erik Stomrud, Sebastian Palmqvist, Oskar Hansson and Rik Ossenkoppele
    Citation: Alzheimer's Research & Therapy 2022 14:144
  33. The protracted preclinical stage of Alzheimer’s disease (AD) provides the opportunity for early intervention to prevent the disease; however, the lack of minimally invasive and easily detectable biomarkers and...

    Authors: Kohei Yuyama, Hui Sun, Yasuyuki Igarashi, Kenji Monde, Takumi Hirase, Masato Nakayama and Yoichi Makino
    Citation: Alzheimer's Research & Therapy 2022 14:140
  34. An active lifestyle is associated with improved cognitive functions in aged people and may prevent or slow down the progression of various neurodegenerative diseases including Alzheimer’s disease (AD). To inve...

    Authors: Jogender Mehla, Scott H. Deibel, Hadil Karem, Shakhawat Hossain, Sean G. Lacoursiere, Robert J. Sutherland, Majid H. Mohajerani and Robert J. McDonald
    Citation: Alzheimer's Research & Therapy 2022 14:143
  35. The individual and complementary value of the Visual Short-Term Memory Binding Test (VSTMBT) and the Free and Cued Selective Reminding Test (FCSRT) as markers to trace the AD continuum was investigated. It was...

    Authors: Mario A. Parra, Clara Calia, Vivek Pattan and Sergio Della Sala
    Citation: Alzheimer's Research & Therapy 2022 14:142
  36. Both cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA) are related to cognitive impairment and dementia. This study aimed to clarify CAA- and HA-related small vessel disease (SVD) imaging ma...

    Authors: Ting-Bin Chen, Wei-Ju Lee, Jun-Peng Chen, Shiang-Yu Chang, Chun-Fu Lin and Hung-Chieh Chen
    Citation: Alzheimer's Research & Therapy 2022 14:141
  37. In Alzheimer’s disease (AD), fibrillar tau initially occurs locally and progresses preferentially between closely connected regions. However, the underlying sources of regional vulnerability to tau pathology r...

    Authors: Anna Rubinski, Nicolai Franzmeier, Anna Dewenter, Ying Luan, Ruben Smith, Olof Strandberg, Rik Ossenkoppele, Martin Dichgans, Oskar Hansson and Michael Ewers
    Citation: Alzheimer's Research & Therapy 2022 14:139
  38. Early detection of individuals at risk for Alzheimer’s disease (AD) is highly important. Amyloid accumulation is an early pathological AD event, but the genetic association with known AD risk variants beyond the

    Authors: Emma S. Luckett, Yasmina Abakkouy, Mariska Reinartz, Katarzyna Adamczuk, Jolien Schaeverbeke, Sare Verstockt, Steffi De Meyer, Koen Van Laere, Patrick Dupont, Isabelle Cleynen and Rik Vandenberghe
    Citation: Alzheimer's Research & Therapy 2022 14:138
  39. This study aimed to identify cases of potential prodromal DLB in very late-onset schizophrenia-like psychosis (VLOSLP), using indicative biomarkers of dementia with Lewy bodies (DLB), and to evaluate the chara...

    Authors: Hideki Kanemoto, Yuto Satake, Takashi Suehiro, Daiki Taomoto, Fuyuki Koizumi, Shunsuke Sato, Tamiki Wada, Keiko Matsunaga, Eku Shimosegawa, Mamoru Hashimoto, Kenji Yoshiyama and Manabu Ikeda
    Citation: Alzheimer's Research & Therapy 2022 14:137
  40. Alzheimer’s disease (AD) is characterized by a reorganization of brain activity determining network hyperexcitability and loss of synaptic plasticity. Precisely, a dysfunction in metabotropic GABAB receptor signa...

    Authors: Alejandro Martín-Belmonte, Carolina Aguado, Rocío Alfaro-Ruiz, Ana Esther Moreno-Martínez, Luis de la Ossa, Ester Aso, Laura Gómez-Acero, Ryuichi Shigemoto, Yugo Fukazawa, Francisco Ciruela and Rafael Luján
    Citation: Alzheimer's Research & Therapy 2022 14:136
  41. Aquaporin-4 (AQP4) is a channel protein that plays a fundamental role in glymphatic system, a newly described pathway for fluid exchange in the central nervous system, as well as a central figure in a fascinat...

    Authors: Andrea Arighi, Marina Arcaro, Giorgio Giulio Fumagalli, Tiziana Carandini, Anna Margherita Pietroboni, Luca Sacchi, Chiara Fenoglio, Maria Serpente, Federica Sorrentino, Giovanni Isgrò, Federico Turkheimer, Elio Scarpini and Daniela Galimberti
    Citation: Alzheimer's Research & Therapy 2022 14:135
  42. Vascular disease is a known risk factor for Alzheimer’s disease (AD). Endothelial dysfunction has been linked to reduced cerebral blood flow. Endothelial nitric oxide synthase pathway (eNOS) upregulation is kn...

    Authors: Elizabeth Degrush, Mohammed Salman Shazeeb, David Drachman, Zeynep Vardar, Clifford Lindsay, Matthew J. Gounis and Nils Henninger
    Citation: Alzheimer's Research & Therapy 2022 14:134
  43. Sex is increasingly recognized as a significant factor contributing to the biological and clinical heterogeneity in AD. There is also growing evidence for the prominent role of DNA methylation (DNAm) in Alzhei...

    Authors: Tiago C. Silva, Wei Zhang, Juan I. Young, Lissette Gomez, Michael A. Schmidt, Achintya Varma, X. Steven Chen, Eden R. Martin and Lily Wang
    Citation: Alzheimer's Research & Therapy 2022 14:133
  44. Quality of life (QoL) is an important outcome from the perspective of patients and their caregivers, in both dementia and pre-dementia stages. Yet, little is known about the long-term changes in QoL over time....

    Authors: Arenda Mank, Judith J. M. Rijnhart, Ingrid S. van Maurik, Linus Jönsson, Ron Handels, Els D. Bakker, Charlotte E. Teunissen, Bart N. M. van Berckel, Argonde C. van Harten, Johannes Berkhof and Wiesje M. van der Flier
    Citation: Alzheimer's Research & Therapy 2022 14:132
  45. Authors: Fatemah A. Sakr, Michel J. Grothe, Enrica Cavedo, Irina Jelistratova, Marie-Odile Habert, Martin Dyrba, Gabriel Gonzalez-Escamilla, Hugo Bertin, Maxime Locatelli, Stephane Lehericy, Stefan Teipel, Bruno Dubois and Harald Hampel
    Citation: Alzheimer's Research & Therapy 2022 14:131

    The original article was published in Alzheimer's Research & Therapy 2019 11:15

  46. Immune system dysregulation plays a vital role in the pathogenesis of neurodegenerative diseases, even considered to be as important as classical pathological protein aggregation assumption. However, the assoc...

    Authors: Ya-Ru Zhang, Liu Yang, Hui-Fu Wang, Bang-Sheng Wu, Shu-Yi Huang, Wei Cheng, Jian-Feng Feng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2022 14:130
  47. Cortical deposition of β-amyloid (Aβ) plaque is one of the main hallmarks of Alzheimer’s disease (AD). While Aβ positivity has been the main concern so far, predicting whether Aβ (−) individuals will convert t...

    Authors: Chae Jung Park, Younghoon Seo, Yeong Sim Choe, Hyemin Jang, Hyejoo Lee and Jun Pyo Kim
    Citation: Alzheimer's Research & Therapy 2022 14:129
  48. Chronic inflammation is a central feature of several forms of dementia. However, few details on the associations of blood-based inflammation-related proteins with dementia incidence have been explored yet.

    Authors: Kira Trares, Megha Bhardwaj, Laura Perna, Hannah Stocker, Agnese Petrera, Stefanie M. Hauck, Konrad Beyreuther, Hermann Brenner and Ben Schöttker
    Citation: Alzheimer's Research & Therapy 2022 14:128
  49. Measurements of the amyloid-β (Aβ) 42/40 ratio in blood plasma may support the early diagnosis of Alzheimer’s disease and aid in the selection of suitable participants in clinical trials. Here, we compared the...

    Authors: Hans-W. Klafki, Jonathan Vogelgsang, Ekaterina Manuilova, Chris Bauer, Alexander Jethwa, Hermann Esselmann, Anke Jahn-Brodmann, Dirk Osterloh, Ingolf Lachmann, Benedict Breitling, Carolin Rauter, Niels Hansen, Caroline Bouter, Stefan Palme, Johannes Schuchhardt and Jens Wiltfang
    Citation: Alzheimer's Research & Therapy 2022 14:127